Comparative bioequivalence study of Glibenclamide 5mg tablet of Dorsa pharmaceutical Co. and Daonil 5 mg tablet of SANOFI as reference in 24 healthy male under fasting.

Dorsa Pharmaceutical Co.0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年8月29日

适应症

试验速览

暂无简介。

•Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range between 18.5 - 30 kg/m2.
•Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
•Subjects that have normal vital signs.
•Subjects who agree with patient consent form.

•Subjects with known allergy to the products tested.
•Acute infection within one week before the first administration of the drug.
•Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.
•Subjects who has used any drug including prescription or Over-The-Counter (OTC) drugs within 7 days prior to the start of the study and might need drug intake during study period.
•History of alcohol or drug abuse within 2 years before the start of the study.
•Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity.
•A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

发起方

Dorsa Pharmaceutical Co.